Modality
ERT
MOA
ALKi
Target
SHP2
Pathway
STING
PNHFLET
Development Pipeline
Preclinical
Nov 2017
→ Oct 2030
PreclinicalCurrent
NCT05687498
121 pts·PNH
2017-11→2030-10·Completed
NCT08033126
142 pts·FL
2024-11→TBD·Recruiting
263 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-054.5y awayInterim· PNH
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Preclinical
Recruit…
Catalysts
Interim
2030-10-05 · 4.5y away
PNH
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05687498 | Preclinical | PNH | Completed | 121 | DOR |
| NCT08033126 | Preclinical | FL | Recruiting | 142 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 |